Prognostic and Predictive Role of Circulating Tumor DNA Detection in Patients with Muscle Invasive Bladder Cancer: a Systematic Review and Meta-analysis

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2025 Mar 2

PMID 40025568

Authors

Xindong Gao

Wenqiang Qi

Junxian Li

Yangyang Xia

Pengzhong Ding

Dongyue Guo

BenKang Shi

Xuewen Jiang

Affiliations

Soon will be listed here.

Abstract

Background: At present, there is no effective prognostic indicator for muscle invasive bladder cancer (MIBC). A liquid biopsy method, plasma circulating tumor DNA (ctDNA) detection, was evaluated for use in predicting the prognosis of different cancers. This study aims to assess the prognostic value of ctDNA state for muscle-invasive bladder cancer patients.

Methods: We comprehensively searched three public databases (PubMed, EMBASE, and the Cochrane Library) in December 2023 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. Studies investigating ctDNA and prognostic outcome indicators in patients with MIBC were included in our analysis. The hazard ratios (HRs) with 95% confidence intervals (CIs) were extracted to evaluate the association between ctDNA and the prognosis in patients with MIBC.

Results: Eleven studies and 1,170 patients diagnosed with muscle-invasive bladder cancer, comprising a total of four retrospective cohort studies and eight prospective cohort studies, included in our meta-analysis, one of which had two different cohorts. The analysis revealed that a positive ctDNA state was associated with poor overall survival (OS), progression-free survival (PFS), and recurrence-free survival (RFS) in patients with MIBC (HR = 4.51, 95% CI: 2.64-7.69, P < 0.001; HR = 4.50, 95% CI: 2.77-7.30, P < 0.001; HR = 6.56, 95% CI: 4.18-10.30, P < 0.001), with significant prognostic effects both pre- and post-treatment. In addition, longitudinal ctDNA analysis proved to be effective in the monitoring of patients with MIBC receiving different treatments (HR = 0.24, 95% CI: 0.14-0.41, P < 0.001).

Conclusions: A positive ctDNA state was associated with poor OS, PFS, and RFS in patients with MIBC pre- and post-treatment. Meanwhile, clearance of ctDNA was associated with improved RFS in patients with MIBC. These findings suggest that the ctDNA state is a predictive and prognostic indicator for patients with MIBC, which can be used to monitor recurrence and guide treatment. Thus, ctDNA level detection shows potential for the treatment and prognosis of patients with MIBC.

References

Huelster H, Gould B, Schiftan E, Camperlengo L, Davaro F, Rose K . Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. Eur Urol. 2023; 85(3):283-292. DOI: 10.1016/j.eururo.2023.09.017. View

Kamat A, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W . Bladder cancer. Lancet. 2016; 388(10061):2796-2810. DOI: 10.1016/S0140-6736(16)30512-8. View

Flaig T, Spiess P, Abern M, Agarwal N, Bangs R, Boorjian S . NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022; 20(8):866-878. DOI: 10.6004/jnccn.2022.0041. View

Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J . Liquid biopsy in cancer current: status, challenges and future prospects. Signal Transduct Target Ther. 2024; 9(1):336. PMC: 11609310. DOI: 10.1038/s41392-024-02021-w. View

Wijaya J, Patel U, Quintero-Consuegra M, Aguilera-Pena M, Madrinan-Navia H, Putra A . Liquid biopsy in the setting of leptomeningeal metastases: a systematic review and meta-analysis. J Neurooncol. 2023; 165(3):431-438. DOI: 10.1007/s11060-023-04519-9. View

Stroup D, Berlin J, Morton S, Olkin I, Williamson G, Rennie D . Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15):2008-12. DOI: 10.1001/jama.283.15.2008. View

Ben-David R, Tillu N, Cumarasamy S, Alerasool P, Rich J, Kaufmann B . Longitudinal Tumor-informed Circulating Tumor DNA Status Predicts Disease Upstaging and Poor Prognosis for Patients Undergoing Radical Cystectomy. Eur Urol Oncol. 2024; 7(5):1105-1112. DOI: 10.1016/j.euo.2024.03.002. View

Abbosh C, Birkbak N, Wilson G, Jamal-Hanjani M, Constantin T, Salari R . Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017; 545(7655):446-451. PMC: 5812436. DOI: 10.1038/nature22364. View

Szabados B, Kockx M, Assaf Z, Van Dam P, Rodriguez-Vida A, Duran I . Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. Eur Urol. 2022; 82(2):212-222. DOI: 10.1016/j.eururo.2022.04.013. View

10.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

11.

Sfakianos J, Basu A, Laliotis G, Cumarasamy S, Rich J, Kommalapati A . Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer. Eur Urol Oncol. 2024; . DOI: 10.1016/j.euo.2024.07.001. View

12.

Witjes J, Bruins H, Carrion A, Cathomas R, Comperat E, Efstathiou J . European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines. Eur Urol. 2023; 85(1):17-31. DOI: 10.1016/j.eururo.2023.08.016. View

13.

Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts R . Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015; 7(302):302ra133. DOI: 10.1126/scitranslmed.aab0021. View

14.

Mohanty S, Lobo A, Mishra S, Cheng L . Precision Medicine in Bladder Cancer: Present Challenges and Future Directions. J Pers Med. 2023; 13(5). PMC: 10222089. DOI: 10.3390/jpm13050756. View

15.

Ma S, An Y, Sun J, Xu M, Liu C, Xu J . The effect of different timing of blood transfusion on oncological outcomes of patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis. Front Oncol. 2023; 13:1223592. PMC: 10499617. DOI: 10.3389/fonc.2023.1223592. View

16.

Tan M, Attard G, Huddart R . Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. Int J Mol Sci. 2018; 19(9). PMC: 6165229. DOI: 10.3390/ijms19092568. View

17.

BinHumaid F, Goel A, Gordon N, Abbotts B, Cheng K, Zeegers M . Circulating Tumour DNA Detection By The Urine-Informed Analysis Of Archival Serum Samples From Muscle-Invasive Bladder Cancer Patients. Eur Urol. 2024; 85(5):508-509. DOI: 10.1016/j.eururo.2024.01.016. View

18.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

19.

Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S . Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2013; 65(2):350-7. DOI: 10.1016/j.eururo.2013.06.049. View

20.

Vandekerkhove G, Lavoie J, Annala M, Murtha A, Sundahl N, Walz S . Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun. 2021; 12(1):184. PMC: 7794518. DOI: 10.1038/s41467-020-20493-6. View